NO133670B - - Google Patents

Download PDF

Info

Publication number
NO133670B
NO133670B NO430/73A NO43073A NO133670B NO 133670 B NO133670 B NO 133670B NO 430/73 A NO430/73 A NO 430/73A NO 43073 A NO43073 A NO 43073A NO 133670 B NO133670 B NO 133670B
Authority
NO
Norway
Prior art keywords
lysergic acid
ester
group
lysergic
acid
Prior art date
Application number
NO430/73A
Other languages
Norwegian (no)
Other versions
NO133670C (en
Inventor
E Mago
T Balogh
E Uskert
J Borsi
L Lf
Original Assignee
Richter Gedeon Vegueszeti Gyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HUGO001186 external-priority patent/HU164051B/hu
Priority claimed from HUGO001187 external-priority patent/HU163546B/hu
Application filed by Richter Gedeon Vegueszeti Gyar filed Critical Richter Gedeon Vegueszeti Gyar
Publication of NO133670B publication Critical patent/NO133670B/no
Publication of NO133670C publication Critical patent/NO133670C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D457/00Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D457/00Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06Lysergic acid amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D457/00Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06Lysergic acid amides
    • C07D457/08Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

Fremgangsmåte ved fremstilling av lysergamider av generell formel I: Procedure for the preparation of lysergamides of general formula I:

hvor :F"*"y "betegner en -CH=C- eller -CH2~CH-gruppe, where :F"*"y "denotes a -CH=C- or -CH2~CH group,

R^betegner et hydrogenatom eller en methylgruppeog R^ denotes a hydrogen atom or a methyl group and

R2betegner en allylgruppe, en fenyl-, pyridyl-, eller pyrimidylgruppe som eventuelt har én eller flere meth- R2 denotes an allyl group, a phenyl, pyridyl or pyrimidyl group which optionally has one or more met

oxy-, halogen-, trifluormethyl- og/e-ller- nitrosubst-itu-enter, en n-propyl- eller n-butyl-gruppe som eventuelt har- én eller flere cårbomethoxy- og/eller nitroguani-dino-substituenter, eller en glycol-tyrosinol-gruppe. oxy, halogen, trifluoromethyl and/or nitrosubstituents, an n-propyl or n-butyl group which optionally has one or more carbomethoxy and/or nitroguanidino substituents, or a glycol-tyrosinol group.

Med uttrykket "lysergsyre" menes^i denne beskrivelse en fullstendig generell angivelse, og således kan uttrykket angri isolyserg-syre, såvel som D-og Ir antipoder eller de racemiske former av syr-ene. R2-gruppen i forbindelsene av generell former I kan likeledes være avledet fra optisk aktive eller inaktive substituerte aminer. In this description, the term "lysergic acid" means a completely general statement, and thus the term can refer to isolysergic acid, as well as D and Ir antipodes or the racemic forms of the acids. The R 2 group in the compounds of general form I may likewise be derived from optically active or inactive substituted amines.

Det er vel kjent at lysergamider er forbindelser av stor medi-sinsk betydning. Således er f.eks. alle av ergotalkaloidene som foreligger i naturen lysergamider.. De semi synt et i ske fremgangsmåter som utgår fra lysergsyre angår i de fleste tilfeller frems-tilling av lysergamider og lysergalkanolamider, siden disse forbindelser i stor graet-utvider den terapeutiske anvendbarhet av lysrergsyredeFivatene. It is well known that lysergamides are compounds of great medical importance. Thus, e.g. all of the ergot alkaloids that exist in nature are lysergamides. The semi-synthetic methods that start from lysergic acid in most cases concern the production of lysergamides and lysergalkanolamides, since these compounds greatly extend the therapeutic applicability of the lysergic acid derivatives.

Det er utviklet flere fremgangsmåter for semisyntetisk- fremstilling av lysergamider. Den fbrste av de vidt anvendte metoder ble utviklet av A. Stoll og A. Hofman (Helv.Chim. Acta 26, I9U-3). Ifolge denne fremgangsmåte ble. lysergpeptider splittet under dannelse av lyserghydrazid som ble omdannet til lyserg-azid, og denne forbindelse ble anvendt ved acylering av forskjellige aminer. En stor ulempe med denne såkalte azidmetode er imidlertid at den forloper med lavt utbytte, og en betydelig mengde av biprodukter- dannes også. Several methods have been developed for the semi-synthetic production of lysergamides. The first of the widely used methods was developed by A. Stoll and A. Hofman (Helv.Chim. Acta 26, I9U-3). According to this procedure, lyserg peptides cleaved to form lyserg hydrazide which was converted to lyserg azide, and this compound was used in the acylation of various amines. However, a major disadvantage of this so-called azide method is that it proceeds with a low yield, and a significant amount of by-products are also formed.

En annen kjent fremgangsmåte er den såkalte blandede anhydricT-koplingsmetode. Ifolge denne metode dannes, et blandet anhydrid fra lysergsyre- og trifluoreddiksyre (US patentskrift nr. 2.736.728) Another known method is the so-called mixed anhydricT coupling method. According to this method, a mixed anhydride from lysergic and trifluoroacetic acid is formed (US patent no. 2,736,728)

eller fra lysergsyre og svoveltrioxyd (tysk patentskrift nr.1.0^0.560), og det erholdte blandede anhyd-rid anvendes ved acylering av alkanol-aminer. Denne fremgangsmåte tillater imidlertid ikke fremstilling av ens lysergalkanolamider. or from lysergic acid and sulfur trioxide (German Patent No. 1.0^0.560), and the resulting mixed anhydride is used in the acylation of alkanol amines. However, this method does not allow the production of identical lysergalcanolamides.

Ifolge en annen- kjent framgangsmåte utfores acyleringen med lyserghalogenider. Fremstilling av de respektive lyserghalogenider er beskrevet i ungarsk patentskrift nr. 150A25 og 151.8^7. Disse fremgangsmåter er imidlertid ufordelaktige i mange henseende, således kan f.eks. syrekloriddannelsen bare utfores under ekstremt aggressive reaksjonsbetingelser (f.eks. ved bruk av fosfortriklorA3 som løsningsmiddel og fosforoxyklorid og fosforpentaklorid som klor-ineringsmiddel), det erholdte syreklorid inneholder en stor mengde av urenheter (forst av alt lysergsyre, uorganiske fosforforbindelser og lysergklorid klorinert også i 2-stillingen), og endelig er det-ikke utviklet noen fremgangsmåte for rensing av syrekloridet. Videre kan acyleringen ved bruk av lysergklorid bare utfores med et utbytte på maksimalt 70$, og urenhetene av lysergkloridet fremkommer også i lysergamidene fremstilt på denne måte. According to another known procedure, the acylation is carried out with lyser halides. Production of the respective lyser halides is described in Hungarian patent documents No. 150A25 and 151.8^7. However, these methods are disadvantageous in many respects, so e.g. the acid chloride formation is only carried out under extremely aggressive reaction conditions (e.g. using phosphorus trichlorA3 as solvent and phosphorus oxychloride and phosphorus pentachloride as chlorinating agents), the resulting acid chloride contains a large amount of impurities (first of all lysergic acid, inorganic phosphorus compounds and lysergic chloride also chlorinated in 2 position), and finally no method has been developed for purifying the acid chloride. Furthermore, the acylation using lysergic chloride can only be carried out with a maximum yield of 70$, and the impurities of the lysergic chloride also appear in the lysergamides produced in this way.

Østerriksk patentskrift nr. 216.679 beskriver en fremgangsmåte ved fremstilling av monosubstituerte lysergamider, ifolge hvilken lysergsyre og et primært amin kondenseres med hverandre i nærvær av carbodiimider. Ved bruk av denne fremgangsmåte, kan det imidlertid ikke oppnåes betydelige utbytter, siden den optisk aktive lysergsyre praktisk talt fullstendig omdannes til den racemiske form under reaksjonsforlopet. Austrian Patent No. 216,679 describes a process for the preparation of monosubstituted lysergamides, according to which lysergic acid and a primary amine are condensed with each other in the presence of carbodiimides. Using this method, however, significant yields cannot be obtained, since the optically active lysergic acid is practically completely converted to the racemic form during the course of the reaction.

Av ytterligere kjente fremgangsmåter ved fremstillingen av lysergalkanolamider skal nevnes den direkte kondensasjon av lysergsyre med aminoalkoholer (Collection 3ij 3^15, 1966), og amidering av lysergsyremethylester (Collection 22, 101^, 1957). Disse fremgangsmåter krever imidlertid meget hoye temperaturer (190 til 200°C) og Of further known methods for the production of lysergic acid canolamides, mention should be made of the direct condensation of lysergic acid with amino alcohols (Collection 3ij 3^15, 1966), and amidation of lysergic acid methyl ester (Collection 22, 101^, 1957). However, these methods require very high temperatures (190 to 200°C) and

lange reaksjonstider (8 til 10 timer), og de forloper med meget lave utbytter. long reaction times (8 to 10 hours), and they proceed with very low yields.

Ved foreliggende oppfinnelse tilveiebringes det en ny fremgangsmåte ved fremstilling av lysergamider, fri for de ulemper som de hit-til kjente metoder er beheftet med, og hvor det fremstilles et meget rent produkt med et godt utbytte ved en lett gjennomfbrbar reaksjon uten dannelse av biprodukter. The present invention provides a new method for the production of lysergamides, free from the disadvantages with which the hitherto known methods have been affected, and where a very pure product is produced with a good yield by an easily carried out reaction without the formation of by-products.

■ Fremgangsmåten ifolge oppfinnelsen er basert på den oppdagelse at lysergamider dannes i fullstendig ren tilstand når aktive lysergsyreestere omsettes med forbindelser inneholdende en primær eller sekundær aminogruppe., Hverken isomerisering eller racematdannelse foregår under reaksjonsforlopet, og syntesen forloper med praktisk talt kvantitativt utbytte. Denne fremgangsmåte kan anvendes uten unntak ved fremstillingen av et hvilket som helst syreamid av lyserg- ■ The method according to the invention is based on the discovery that lysergamides are formed in a completely pure state when active lysergic acid esters are reacted with compounds containing a primary or secondary amino group. Neither isomerization nor racemate formation takes place during the course of the reaction, and the synthesis proceeds with a practically quantitative yield. This method can be used without exception in the preparation of any acid amide of lyserg-

syre, N-alkyl-iysergsyrer, 9,10-dihydro-lysergsy.re og N-alkyl-9,10-dihydro-lysergsyrer. acid, N-alkyl-lysergic acids, 9,10-dihydro-lysergic acids and N-alkyl-9,10-dihydro-lysergic acids.

Foreliggende oppfinnelse angår altså en ny fremgangsmåte ved fremstilling av lysergsyreamider av generell formel I, og deres syreaddisjonssalter, hvilken fremgangsmåte erkarakterisert vedat en aktiv lysergsyreester av gererell formel II: The present invention therefore relates to a new process for the production of lysergic acid amides of general formula I, and their acid addition salts, which process is characterized by an active lysergic acid ester of general formula II:

hvor x~^"y og R-, har de tidligere angitte betydninger^ Z betegner where x~^"y and R-, have the previously indicated meanings^ Z denotes

halogenatomer og/eller nitrogrupper, og n er en faktor fra 1 - 55amideres med en forbindelse inneholdende en primær eller sekundær aminogruppe, og om onskes, at den erholdte forbindelse av generell formel I omdannes til et syreaddisjonssalt ved omsetning med en farmasøytisk akseptabel syre. halogen atoms and/or nitro groups, and n is a factor from 1 - 55 is amidated with a compound containing a primary or secondary amino group, and if desired, the resulting compound of general formula I is converted into an acid addition salt by reaction with a pharmaceutically acceptable acid.

En gruppe av de nye forbindelser utviser spesifikk antisero-"tonisk aktivitet. Ifolge utforte forsok på isolerte organer under in vitro betingelser inhiberte disse forbindelser den glattmuskel-kontraksjonsaktivitet som var fremkalt av serotonin, mens de under in vivo betingelser virket som antagonister i lave doser til de inflammasjons-induserende og sirkulasjons-influerende virkninger av serotonin. En annen gruppe av de nye forbindelser utviste en betydelig depressiv aktivitet på det sentrale nervesystem, således under-trykker de den spontane motilitet hos testdyr og virker som antagon-ist til den stimuelerende aktivitet fremkalt av psykostimulerende farmasoytika, f.eks. amfetamin. En ytterligere gruppe av forbindelsene med antidepressiv aktivitet utviste aktiviteter tilsvarende de tricycliske antidepressiva. Ved "forsok utfort på rotter og mus virket de som antagonister til de neuroleptiske aktiviteter fremkalt av reserpin og potensiverte den psykostimulerende aktivitet til amfetamin. Disse forbindelser er imidlertid forskjellige fra de tricycliske antidepressiva på det vis at de ikke oker vasopressorakti-viteten av noradrenalin. A group of the new compounds exhibits specific antiserotonic activity. According to experiments carried out on isolated organs under in vitro conditions, these compounds inhibited the smooth muscle contraction activity induced by serotonin, while under in vivo conditions they acted as antagonists at low doses to the inflammation-inducing and circulation-influencing effects of serotonin. Another group of the new compounds exhibited a significant depressant activity on the central nervous system, thus suppressing the spontaneous motility of test animals and acting as an antagonist to the stimulating activity evoked of psychostimulant pharmaceuticals, e.g. amphetamine. A further group of compounds with antidepressant activity exhibited activities similar to the tricyclic antidepressants. In "experiments carried out on rats and mice, they acted as antagonists to the neuroleptic activities elicited by reserpine and potentiated the psychostimulant activity of amphetamine . However, these compounds differ from the tricyclic antidepressants in that they do not increase the vasopressor activity of norepinephrine.

Forbindelsene av generell formel II, som anvendes som utgangs-materialer ved fremgangsmåten ifolge oppfinnelsen, kan fremstilles ved at lysergsyrer av generell formel III: hvor R-, og har de tidligere angitte betydninger, omsettes med fenoler av generell formel IV: The compounds of general formula II, which are used as starting materials in the process according to the invention, can be prepared by reacting lysergic acids of general formula III: where R-, and have the previously indicated meanings, with phenols of general formula IV:

hvor Z og n har de tidligere angitte betydninger, i nærvær av de-hydratiseringsmidler. where Z and n have the previously stated meanings, in the presence of dehydrating agents.

Blant de aktive lysergsyreestere kan fortrinnsvis pentaklor-fenolater anvendes. Reaksjonen utfores fortrinnsvis i nærvær av et inert løsningsmiddel, slik som tetrahydrofuran, acetonitril, methylen-klorid eller dimethylformamid. De aktive lysergsyreestere kan anvendes i isolert form, men reaksjonen kan også utfores ved bruk av den reaksjonsblanding hvor disse aktive estere er dannet. Among the active lysergic acid esters, pentachlorophenolates can preferably be used. The reaction is preferably carried out in the presence of an inert solvent, such as tetrahydrofuran, acetonitrile, methylene chloride or dimethylformamide. The active lysergic acid esters can be used in isolated form, but the reaction can also be carried out using the reaction mixture in which these active esters are formed.

Som aminoreagenser kan en hvilken som helst substituert amin-forbindelse anvendes slik som mono- eller fle-rverdige aminoalkoholer, mono- eller disubstituerte- alkylaminer, aminosyrer, di- eller tri-peptider, monosubstituerte piperaziner, arylaminer, f.eks. anilin og anilinderivater, aminopyridiner etc_ As amino reagents, any substituted amine compound can be used such as mono- or polyhydric amino alcohols, mono- or di-substituted alkyl amines, amino acids, di- or tri-peptides, mono-substituted piperazines, aryl amines, e.g. aniline and aniline derivatives, aminopyridines etc_

Oppfinnelsen åpenbarer flere fordeler,, blant hvilke folgende spesielt skal nevnes: a) den nye fremgangsmåte kan utfores uten unntak ved fremstilling av et hvilket som helst substituert lysergamid,. The invention reveals several advantages, among which the following should be particularly mentioned: a) the new method can be carried out without exception in the preparation of any substituted lysergamide.

b) reaksjonen kan utfores i en enkel prosess, b) the reaction can be carried out in a simple process,

c) ingen biprodukter dannes under reaksjonsforlopet, c) no by-products are formed during the course of the reaction,

d) reaksjonen forloper med hoyt utbytte, d) the reaction proceeds with a high yield,

e) forbindelsene er av hoy renhetsgrad og utviser verdifulle e) the compounds are of high purity and exhibit valuable properties

farmakologiske egenskaper. pharmacological properties.

Oppfinnelsen skal ytterligere illustreres ved de etterfølgende eksempler. The invention shall be further illustrated by the following examples.

Eksempel 1 Example 1

Fremstilling av l- methyl- 9. 10- dihydro- d- lysergsyre- C^- methoxy)- anilid Preparation of l- methyl- 9. 10- dihydro- d- lysergic acid- C^- methoxy)- anilide

5,53 g l-methyl-9,10-dihydro-d-lysergsyre-pentaklorfenolester ble lost i 100 ml torr kloroform under omrbring, deretter ble lbsningen avkjblt med isvann og 1,35 g p-methoxy-anilin lost i 10 ml kloroform ble dråpevis tilsatt. Lbsningen ble omrbrt ved romtemperatur i en time, deretter ble den ekstrahert - med 6x25 ml 1%- ig vandig vinsyrelbsning. De vandige ekstrakter ble kombinert, og blandingens pH ble justert til 8 ved tilsats av noen milliliter 10$-ig vandig aiiimoniumhydroxydlbsning. Den vandige lbsning ble rystet med 5x50 ml kloroform. Kloroformlbsningen ble kombinert, tbrket over natrium-sulfat, filtrert og fordampet i vakuum. Residuet ble lost i 10 ml 5.53 g of l-methyl-9,10-dihydro-d-lysergic acid pentachlorophenol ester was dissolved in 100 ml of dry chloroform with stirring, then the solution was quenched with ice water and 1.35 g of p-methoxy-aniline was dissolved in 10 ml of chloroform was added dropwise. The solution was stirred at room temperature for one hour, then it was extracted - with 6x25 ml of 1% aqueous tartaric acid solution. The aqueous extracts were combined, and the pH of the mixture was adjusted to 8 by the addition of a few milliliters of 10 µg aqueous ammonium hydroxide solution. The aqueous solution was shaken with 5x50 ml of chloroform. The chloroform solution was combined, dried over sodium sulfate, filtered and evaporated in vacuo. The residue was dissolved in 10 ml

benzen og benzenlosningen ble helt over i 300 ml torr petroleumether. Det utskilte bunnfall ble filtrert fra, og vasket med en liten mengde petroleumether og tbrket i vakuum. Produktet ble underkastet kromatografi på en aluminiumoxydkolonne, ved bruk av en 8:2 blanding av kloroform og benzen som elueringsmiddel. På denne måte ble det erholdt 3,56 g (91$) l-methyl-9,10-dihydro-d-lysergsyre-(^-methoxy)-anilid med smeltepunkt I59°C. benzene and the benzene solution was poured into 300 ml of dry petroleum ether. The separated precipitate was filtered off, washed with a small amount of petroleum ether and dried in vacuo. The product was subjected to chromatography on an aluminum oxide column, using an 8:2 mixture of chloroform and benzene as eluent. In this way, 3.56 g (91$) of 1-methyl-9,10-dihydro-d-lysergic acid-(^-methoxy)-anilide with a melting point of 159°C were obtained.

Utgangsmaterialet, l-methyl-9,10-dihydro-d-lysergsyre-pentaklorfenolester ble fremstilt som folger: l,1+3 g l-methyl-9,10-dihydro-d-lysergsyre fritt for vann ble suspendert i en blandinga av 60 ml absolutt tetrahydrofuran og 60 ml absolutt diklormethan, hvoretter 1,35 g pentaklorfenol ble tilsatt. Den erholdte losning ble avkjblt under omrbring til en temperatur mellom 0° og 5°C, og i små porsjoner ble 1,25 g dicyclohexylcarbo-diimid tilsatt i lopet av 2 timer. Losningen ble gradvis oppvarmet til 20° og omrbrt i flere timer. Dicyclohexylurea utskilt i krys-tallinsk form ble filtrert og vasket med 10 ml tetrahydrofuran. Filtratet og vaskevæsken ble forent og fordampet til tbrrhet under redusert trykk. Det torre residuum ble opplost varmt i 5 ml benzen og- den erholdte losning ble helt over under omrbring i 50 ml petroleumether. Den erholdte suspensjon ble behandlet med is i lbpet av 2h timer, hvoretter produktet ble filtrert, vasket med 20 ml kald petroleumether og tbrket under vakuum. The starting material, l-methyl-9,10-dihydro-d-lysergic acid pentachlorophenol ester was prepared as follows: 1.1+3 g of l-methyl-9,10-dihydro-d-lysergic acid free of water was suspended in a mixture of 60 ml of absolute tetrahydrofuran and 60 ml of absolute dichloromethane, after which 1.35 g of pentachlorophenol was added. The resulting solution was cooled with stirring to a temperature between 0° and 5°C, and 1.25 g of dicyclohexylcarbodiimide was added in small portions over the course of 2 hours. The solution was gradually heated to 20° and stirred for several hours. Dicyclohexylurea separated in crystalline form was filtered and washed with 10 ml of tetrahydrofuran. The filtrate and washings were combined and evaporated to dryness under reduced pressure. The dry residue was dissolved hot in 5 ml of benzene and the solution obtained was poured under stirring into 50 ml of petroleum ether. The resulting suspension was treated with ice for 2 hours, after which the product was filtered, washed with 20 ml of cold petroleum ether and dried under vacuum.

Utbytte: 2,0 g (75$), (a>p° = -20° (c- = 0,5 ethanol). Yield: 2.0 g ($75), (a>p° = -20° (c- = 0.5 ethanol).

Eksempel 2 Example 2

Fremstilling av d- lysergsyre-(^- methoxy)- anilid Preparation of d-lysergic acid-(^-methoxy)-anilide

Denne forbindelse ble fremstilt som beskrevet i Eksempel 1, fra 5,37 g d-lysergsyrepentaklorfenolester og 1,5 g p-methoxy-anilin. Produktet ble erholdt med et utbytte på 8*f$ (3,1^ g) og smeltet ved 127°C. This compound was prepared as described in Example 1, from 5.37 g of d-lysergic acid pentachlorophenol ester and 1.5 g of p-methoxyaniline. The product was obtained in a yield of 8% (3.1 g) and melted at 127°C.

Utgangsforbindelsen, d-lysergsyrepentaklorfenolester ble fremstilt fra d-lysergsyre og pentaklorfenol på tilsvarende måte som beskrevet i Eksempel 1. The starting compound, d-lysergic acid pentachlorophenol ester was prepared from d-lysergic acid and pentachlorophenol in a similar manner as described in Example 1.

Utbytte: 62$(a)^° = +31° (c = 0,5 ethanol). Yield: 62$(a)^° = +31° (c = 0.5 ethanol).

Eksempel 3 Example 3

Fremstilling av 9. 10- dihydro- d- lysergsyre-( 1+- methoxy)- anllid Denne forbindelse ble fremstilt som beskrevet i Eksempel 1 fra 5,39 g 9,10-dihydro-d-lysergsyrepentaklorfenolester og 1,5 g p-methoxy-anilin. 3,1 g (82,5$) av tittelforbindelsen ble erholdt, sm.p. l6k°C. Preparation of 9. 10-dihydro-d-lysergic acid-(1+-methoxy)-anllide This compound was prepared as described in Example 1 from 5.39 g of 9,10-dihydro-d-lysergic acid pentachlorophenol ester and 1.5 g of p- methoxyaniline. 3.1 g (82.5$) of the title compound was obtained, m.p. 16k°C.

Utgangsforbindelsen 9,10-dihydro-d-lysergsyrepentaklorfenolester ble fremstilt fra 9,10-dihydro-d-lysergsyre og pentaklorfenol på tilsvarende måte som beskrevet i Eksempel 1. The starting compound 9,10-dihydro-d-lysergic acid pentachlorophenol ester was prepared from 9,10-dihydro-d-lysergic acid and pentachlorophenol in a similar way as described in Example 1.

Utbytte: 69,5$, (a)^° = +3° (c = 0,5 ethanol). Yield: 69.5$, (a)^° = +3° (c = 0.5 ethanol).

Eksempel h Example h

Fremstilling av d- lysergsyre- 6-( If- klor- 5- nitropyi imidin)- amid Preparation of d-lysergic acid-6-(If-chloro-5-nitropyimidine)-amide

Denne forbindelse ble fremstilt som beskrevet i Eksempel 1 This compound was prepared as described in Example 1

fra 5,37 g d-lysergsyrepentaklorfenolester og 2,0 g ^-klor-5-nitro-6-amir.o-pyrimidin. 3,2 g (7*+$) av tittelf orbindelsen ble erholdt, sm.p. 2<>>+0°C. from 5.37 g of d-lysergic acid pentachlorophenol ester and 2.0 g of ^-chloro-5-nitro-6-amir.o-pyrimidine. 3.2 g (7*+$) of the title compound were obtained, m.p. 2<>>+0°C.

Utgangsforbindelsen, d-lysergsyrepentaklorfenolester ble fremstilt som beskrevet i Eksempel 2. The starting compound, d-lysergic acid pentachlorophenol ester was prepared as described in Example 2.

Eksempel 5 Example 5

Fremstilling av 9«10- dihydro- d- lysergsyre- 2-( 5- brom- pyridin)- amid Preparation of 9,10-dihydro-d-lysergic acid-2-(5-bromo-pyridine)-amide

Forbindelsen ble fremstilt som beskrevet i Eksempel 1 fra The compound was prepared as described in Example 1 from

^,70 g 9,10-dihydro-d-lysergsyre-(2,lf, 5-triklorfenol)-ester og 2,0 g 2-amino-5-brompyridin. Det ble erholdt 3,5 g (80$) av tittelforbindelsen med sm.p. 132°C. ^.70 g of 9,10-dihydro-d-lysergic acid-(2,1f,5-trichlorophenol)-ester and 2.0 g of 2-amino-5-bromopyridine. 3.5 g (80$) of the title compound was obtained, m.p. 132°C.

Utgangsmaterialene 9,10-dihydro-d-lysergsyre-(2,^1-, 5-triklor-fenol)-ester, ble fremstilt fra 9,10-dihydro-d-lysergsyre og triklor-fenol på tilsvarende måte som beskrevet i Eksempel 1. The starting materials 9,10-dihydro-d-lysergic acid-(2,^1-,5-trichlorophenol)-ester were prepared from 9,10-dihydro-d-lysergic acid and trichlorophenol in a similar manner as described in Example 1.

Eksempel 6 Example 6

Fremstilling av l- methyl- 9. 10- dihydro- d- lysergylglycyl- tyrosinol Preparation of l- methyl- 9. 10- dihydro- d- lysergylglycyl- tyrosinol

Denne forbindelse ble fremstilt som beskrevet i Eksempel 1 This compound was prepared as described in Example 1

fra 5,53 g l-methyl-9,10-d-lysergsyrepentaklorfenolester og 2,8 g glycyl-tyrosinol. Det ble erholdt ^,5 g (89$) av tittelforbindelsen med sm.p. 152°C. from 5.53 g of l-methyl-9,10-d-lysergic acid pentachlorophenol ester and 2.8 g of glycyl-tyrosinol. There was obtained ^.5 g (89$) of the title compound, m.p. 152°C.

Utgangsmaterialet, l-methyl-9,10-d-lysergsyrepentaklorfenolester, ble fremstilt som beskrevet i Eksempel 1. The starting material, 1-methyl-9,10-d-lysergic acid pentachlorophenol ester, was prepared as described in Example 1.

Eksempel 7 Example 7

Fremstilling av 9. lO- dihydro- d- lysergsyre- f3- trifluormethyl)- anilid Preparation of 9. lO- dihydro- d- lysergic acid- (3- trifluoromethyl)- anilide

Denne forbindelse ble fremstilt som beskrevet i Eksempel 1 fra 5?39g 9,10-dihydro-d-lysergsyrepentaklorfenolester og 2,0 g 3-trifluormethyl-anilin. 3,1 g (72$) av tittelforbindelsen ble erholdt. This compound was prepared as described in Example 1 from 5.39 g of 9,10-dihydro-d-lysergic acid pentachlorophenol ester and 2.0 g of 3-trifluoromethyl-aniline. 3.1 g (72$) of the title compound was obtained.

Sm.p. 130°C.- Sm.p. 130°C.-

Utgangsmaterialet 9,10-dihydro-d-lysergsyrepentaklorfenolester ble fremstilt som beskrevet i Eksempel 3»The starting material 9,10-dihydro-d-lysergic acid pentachlorophenol ester was prepared as described in Example 3"

Eksempel 8 Example 8

Fremstilling av l-methyl-9,10-dihydro-d-lysergsyre-(3-trifluormethyl)- anilid Preparation of l-methyl-9,10-dihydro-d-lysergic acid-(3-trifluoromethyl)-anilide

Denne forbindelse ble fremstilt som beskrevet i Eksempel 1 This compound was prepared as described in Example 1

fra ^,.05 g l-methyl-9,10-dihydro-d-lysergsyre-(^-nitro-f enol-ester og 2,0 g 3-trifluormethylanilin. 2,9 g (68$) av tittelforbindelsen ble erholdt. Sm.p. 2l+2°C. from ^.05 g of 1-methyl-9,10-dihydro-d-lysergic acid-(^-nitro-phenol ester and 2.0 g of 3-trifluoromethylaniline. 2.9 g (68$) of the title compound was obtained Melting point 2l+2°C.

Utgangsmaterialet, l-methyl-9,10-dihydro-d-lysergsyre-(lf-nitro-fenol)-ester ble fremstilt fra l-methyl-9,10-dihydro-d-lysergsyre og ^--nitrofenol som beskrevet i Eksempel 1, med det unntak at amideringen ble utfort i losningen av aktiv ester erholdt etter frafiltrering av dicyclohexylurea. The starting material, l-methyl-9,10-dihydro-d-lysergic acid (l-nitrophenol) ester was prepared from l-methyl-9,10-dihydro-d-lysergic acid and ^-nitrophenol as described in Example 1, with the exception that the amidation was carried out in the solution of active ester obtained after filtering off dicyclohexylurea.

Eksempel 9 Example 9

Fremstilling av d- lysergsyre- allylamidmaleat Preparation of d-lysergic acid allyl amide maleate

Den fri base ble fremstilt som beskrevet i Eksempel 1 fra The free base was prepared as described in Example 1 from

5,37 g d-lysergsyrepentaklorfenolester og 1,0 g 1-allylamin. Den erholdte fri base etter kromatografi ble lost i 20 ml varm ethanol, og 1,2 g maleinsyre lost i 5 ml ethanol ble tilsatt til losningen. Det utskilte krystallinske salt ble filtrert fra,' vasket med en liter, mengde ka]d ethanol og tbrket. Det ble erholdt 3,6 g (8^-$) av tittelforbindelsen, med sm.p. 179°C. 5.37 g of d-lysergic acid pentachlorophenol ester and 1.0 g of 1-allylamine. The free base obtained after chromatography was dissolved in 20 ml of hot ethanol, and 1.2 g of maleic acid dissolved in 5 ml of ethanol was added to the solution. The separated crystalline salt was filtered off, washed with one liter of ethanol and used. 3.6 g (8^-$) of the title compound were obtained, m.p. 179°C.

Utgangsmaterialet, d-lysergsyrepentaklorfenolester, ble fremstilt som beskrevet i Eksempel 2. The starting material, d-lysergic acid pentachlorophenol ester, was prepared as described in Example 2.

Eksempel 10 Example 10

Fremstilling av 1- me thyl- 9 ., 10- dihydro- d- lysergsyre- allylamid Preparation of 1-methyl-9,10-dihydro-d-lysergic acid allylamide

Denne forbindelse ble fremstilt som beskrevet i Eksempel 1 fra 5,53 g l-methyl-9,10-dihydro-d-lysergsyrepentaklorfenolester og 1,0 g 1-allylamin. 3,1 g (96$) av tittelforbindelsen ble erholdt. Sm.p. 189°C. This compound was prepared as described in Example 1 from 5.53 g of 1-methyl-9,10-dihydro-d-lysergic acid pentachlorophenol ester and 1.0 g of 1-allylamine. 3.1 g ($96) of the title compound was obtained. Sm.p. 189°C.

Utgangsmaterialet, l-methyl-9,10-dihydro-d-lysergsyrepentaklorfenolester, ble fremstilt som beskrevet i Eksempel 1. The starting material, 1-methyl-9,10-dihydro-d-lysergic acid pentachlorophenol ester, was prepared as described in Example 1.

Eksempel 11 Example 11

Fremstilling av d- lysergsyre- 2-( l- hydroxy- butan)- amid- maleat Preparation of d-lysergic acid-2-(1-hydroxy-butane)-amide maleate

Denne forbindelse ble fremstilt som beskrevet i Eksempel 9 This compound was prepared as described in Example 9

fra 5,37 g d-lysergsyrepentaklorfenolester og 1,1 g (+)-1-hydroxy-.2-amino-butan. 3,85 g (8^,5$) av tittelforbindelsen ble erholdt. Sm.p. 200°C; (a)^° +^7,0° (c = 1,0 i vann). from 5.37 g d-lysergic acid pentachlorophenol ester and 1.1 g (+)-1-hydroxy-.2-amino-butane. 3.85 g (8^.5$) of the title compound was obtained. Sm.p. 200°C; (a)^° +^7.0° (c = 1.0 in water).

Utgangsforbindelsen d-lysergsyrepentaklorfenolester, ble fremstilt som beskrevet i Eksempel 2. The starting compound d-lysergic acid pentachlorophenol ester was prepared as described in Example 2.

Eksempel 12 Example 12

Fremstilling av l- methyl- d- lysergsyre- 2-( l- hydroxybutan)- amidmaleat Preparation of l-methyl-d-lysergic acid-2-(l-hydroxybutane)-amide maleate

Denne forbindelse ble fremstilt som beskrevet i Eksempel 9 This compound was prepared as described in Example 9

fra 5,51 g 1-methyl-d-lysergsyrepentaklorfenolester og 1,1 g (+)-l-hydroxy-2-aminobutan. ^jl2 g (85$) av tittelforbindelsen ble erholdt, sm.p. 183°C, (cOp = +^2,0° (c = 0, k i vann). from 5.51 g of 1-methyl-d-lysergic acid pentachlorophenol ester and 1.1 g of (+)-1-hydroxy-2-aminobutane. ^jl2 g (85$) of the title compound was obtained, m.p. 183°C, (cOp = +^2.0° (c = 0, k in water).

Utgangsforbindelsen, 1-methyl-d-lysergsyrepentaklorfenolester ble fremstilt fra 1-methyl-d-lysergsyre og pentaklorfenol på tilsvarende måte som beskrevet i Eksempel 1. The starting compound, 1-methyl-d-lysergic acid pentachlorophenol ester was prepared from 1-methyl-d-lysergic acid and pentachlorophenol in a similar way as described in Example 1.

Utbytte: 68$, (a)^° = + lk° (c = 0,5, ethanol). Yield: 68$, (a)^° = + lk° (c = 0.5, ethanol).

Eksempel 13 Example 13

■Fremstilling av 9,10-dihydro-d-lysergsyre-(If-p-hydroxypropyl)-piperazidmaleat ■Preparation of 9,10-dihydro-d-lysergic acid-(If-p-hydroxypropyl)-piperazide maleate

Denne forbindelse ble fremstilt som beskrevet i Eksempel 9 This compound was prepared as described in Example 9

fra 5,39 g 9,10-dihydro-d-lysergsyrepentaklorfenolester og 1,75 g p-hydroxy-propyl-piperazin. Det ble erholdt U-,9 g (93$) av tittelforbindelsen. Sm.p. 207°C; ( a)^ ° = - k9° (c = 0,5 i 50$ vandig ethanol). from 5.39 g of 9,10-dihydro-d-lysergic acid pentachlorophenol ester and 1.75 g of p-hydroxy-propyl-piperazine. U-.9 g ($93) of the title compound was obtained. Sm.p. 207°C; ( a)^ ° = - k9° (c = 0.5 in 50$ aqueous ethanol).

Utgangsforbindelsen, 9,10-dihydro-d-lysergsyrepentaklorfenolester, ble fremstilt som beskrevet i Eksempel 3-The starting compound, 9,10-dihydro-d-lysergic acid pentachlorophenol ester, was prepared as described in Example 3-

Eksempel lh Example lh

Fremstilling av l-methyl-9,10-dihydro-d-lysergyl-uj-nitro-L-arglninmethylester Preparation of l-methyl-9,10-dihydro-d-lysergyl-uj-nitro-L-arglnine methyl ester

5,53 g l-methyl-9,10-dihydro-d-lysergsyrepentaklorfenolester ble lost i en blanding av 50 ml kloroform Og 50 ml tetrahydrofuran under omroring, og 3?5-g L-u)-nitro-L-argininmethylester-hydroklorid lost i en blanding av 20 ml- kloroform og 8 ml triethylamin ble tilsatt til den avkjolte losning". Reaks jons bl an ding en ble omrort ved romtemperatur i 2 timer, deretter ble den ekstrahert med 5 x 30 ml l$-ig vandig vinsyre. Deretter gikk man frem som beskrevet i Eksempel 1. h, 2 g (86,5$) av tittelforbindelsen ble erholdt. Sm.p. 5.53 g of l-methyl-9,10-dihydro-d-lysergic acid pentachlorophenol ester was dissolved in a mixture of 50 ml of chloroform and 50 ml of tetrahydrofuran with stirring, and 3?5 g of L-u)-nitro-L-arginine methyl ester hydrochloride was dissolved in a mixture of 20 ml chloroform and 8 ml triethylamine was added to the cooled solution". The reaction mixture was stirred at room temperature for 2 hours, then it was extracted with 5 x 30 ml 1% aqueous tartaric acid. The procedure then proceeded as described in Example 1. h, 2 g (86.5$) of the title compound was obtained.

220°C. 220°C.

Utgangsf orbindelsen l-methyl-9 ,10-dihydro-d-r.lysergsyrepentaklorfenolester ble fremstilt som beskrevet i Eksempel 1. The starting compound 1-methyl-9,10-dihydro-d-r.lysergic acid pentachlorophenol ester was prepared as described in Example 1.

Eksempel 15 Example 15

Fremstilling av d- lysergsyredimethylamid Preparation of d-lysergic acid dimethylamide

Denne forbindelse ble fremstilt som beskrevet i Eksempel 1 fra 2,7 g d-lysergsyrepentaklorfenolester og 0,5 g dlmethylamin.- 1,3 g This compound was prepared as described in Example 1 from 2.7 g d-lysergic acid pentachlorophenol ester and 0.5 g dlmethylamine.- 1.3 g

■ (88$) av tittelforbindelsen ble erholdt, (a>^0 =-+30° fi-pyridin). ■ (88$) of the title compound was obtained, (a>^0 =-+30° fi-pyridine).

Utgangsforbindelsen, d-lysergsyrepentaklorfenolester, ble fremstilt som beskrevet i Eksempel 2. The starting compound, d-lysergic acid pentachlorophenol ester, was prepared as described in Example 2.

Eksempel 16 Example 16

Fremstilling av d- lysergyl- L-( + ) - cc- aminosmorsyre- methylestermaleat Preparation of d-lysergyl-L-( + )-cc- aminosuccinic acid methyl ester maleate

1,7 g L-(+)-2-amino-smorsyremethylesterhydroklorid (sm.p. 9<*>+-96°C; (a)p° = +21° (c =-5, i- 20$ saltsyre) ble suspendert i 150 ml kloroform,- og suspensjonen ble avkjolt til 10°C. h ml triethylamin ble dråpevis tilsatt til den omrorte susp"ensjon, deretter ble 5,37 g d-lysergsyrepentaklorfenylester drysset til den erholdte suspensjon, og blandingen ble omrort i 30 minutter. Reaksjonsblandingen ble for-tynnet med 30u ml kloroform og ekstrahert med 2 x 50 ml 1%- ig vandig vinsyre. pH til de kombinerte vandige ekstrakter .ble justert til 7 til 7,5 ved bruk av 10$ vandig ammoniumhydroxyd, og denne vandige 1.7 g of L-(+)-2-amino-butyric acid methyl ester hydrochloride (m.p. 9<*>+-96°C; (a)p° = +21° (c =-5, i- 20$ hydrochloric acid ) was suspended in 150 ml of chloroform, and the suspension was cooled to 10°C. 1 ml of triethylamine was added dropwise to the stirred suspension, then 5.37 g of d-lysergic acid pentachlorophenyl ester was sprinkled into the obtained suspension, and the mixture was stirred for 30 minutes. The reaction mixture was diluted with 30 µl chloroform and extracted with 2 x 50 ml 1% aqueous tartaric acid. The pH of the combined aqueous extracts was adjusted to 7 to 7.5 using 10 µl aqueous ammonium hydroxide, and this watery one

losning ble ekstrahert med h x 50 ml kloroform. De organiske faser ble kombinert, tbrket over vannfritt magnesiumsulfat,. filtrert og fordampet til torrhet i vakuum. Residuet ble lost i 30 ml varm ethanol og 1,6 g maleinsyre lost i 6 ml ethanol ble tilsatt til denne los- solution was extracted with h x 50 ml chloroform. The organic phases were combined, dried over anhydrous magnesium sulfate. filtered and evaporated to dryness in vacuo. The residue was dissolved in 30 ml of hot ethanol and 1.6 g of maleic acid dissolved in 6 ml of ethanol was added to this solution.

ning. Den erholdte suspensjon ble kjolt i is i flere timer, hvoretter bunnfallet ble filtrert fra, vasket med 10 ml ethanol og torket i vakuum. Det ble erholdt 3,17 g (86$) av tittelforbindelsen. Sm.p. 200°C (spaltning), ( oc)^ ° = +35° (c = 1, i 50$ vandig ethanol). nothing. The obtained suspension was cooled in ice for several hours, after which the precipitate was filtered off, washed with 10 ml of ethanol and dried in vacuum. 3.17 g (86$) of the title compound was obtained. Sm.p. 200°C (decomposition), (oc)^ ° = +35° (c = 1, in 50$ aqueous ethanol).

Utgangsforbindelsen, d-lysergsyrepentaklorfenolester,. ble fremstilt som beskrevet i Eksempel 2. The starting compound, d-lysergic acid pentachlorophenol ester,. was prepared as described in Example 2.

Eksempel 17 Example 17

Fremstilling av l-methyl-d-lysergyl-L-(+)-a-aminosmorsyre-methylestermaleat Preparation of l-methyl-d-lysergyl-L-(+)-α-aminosuccinic acid methyl ester maleate

Denne forbindelse ble fremstilt som beskrevet i Eksempel 16, fra 5,55 g 1-methyl-d-lysergsyrepentaklorfenolester og 1,7 g L-(+)-2-aminosmorsyre-methylesterhydroklorid. Det ble erholdt This compound was prepared as described in Example 16, from 5.55 g of 1-methyl-d-lysergic acid pentachlorophenol ester and 1.7 g of L-(+)-2-aminosuccinic acid methyl ester hydrochloride. It was obtained

3,21 g (8^f$) av tittelforbindelsen. Sm.p. 178°C (spaltning); 3.21 g (8^f$) of the title compound. Sm.p. 178°C (decomposition);

(oc)p° = +17,3° (c = 1, i 50$ vandig ethanol). (oc)p° = +17.3° (c = 1, in 50$ aqueous ethanol).

Utgangsforbindelsen, 1-methyl-d-lysergsyrepentaklorf enolester, ble fremstilt som beskrevet i Eksempel 12. The starting compound, 1-methyl-d-lysergic acid pentachlorophenol ester, was prepared as described in Example 12.

Eksempel 18 Example 18

Fremstilling av d- lysergyl- l- alaninmethylester Preparation of d-lysergyl-l-alanine methyl ester

Denne forbindelse ble.fremstilt som beskrevet i Eksempel 1 This compound was prepared as described in Example 1

fra h, 82 g d-lysergsyre-2,1+, 5-triklorfenylester og 1,6 g 1-alanin-methylesterhydroklorid. Det ble erholdt 3,1 g(88$) av tittelforbindelsen. (a) D = -6^-° (c = 1 i kloroform), from h, 82 g of d-lysergic acid-2,1+, 5-trichlorophenyl ester and 1.6 g of 1-alanine methyl ester hydrochloride. 3.1 g ($88) of the title compound was obtained. (a) D = -6^-° (c = 1 in chloroform),

Utgangsmaterialet, d-lysergsyre-2, k,5-trlklorfenylester, ble fremstilt fra d-lysergsyre og 2,*+, 5-triklorf enol som beskrevet i Eksempel 1 med det unntak at amideringen ble utfort i losniagen The starting material, d-lysergic acid-2,k,5-trichlorophenyl ester, was prepared from d-lysergic acid and 2,*+,5-trichlorophenol as described in Example 1 with the exception that the amidation was carried out in solvent

av den aktive ester erholdt efter _frafiltrering av dicyclohexylurea. of the active ester obtained after filtration of dicyclohexylurea.

Claims (3)

1. Fremgangsiiråte ved fremstilling av lysergamider av generell formel I: 1. Procedure for the production of lysergamides of general formula I: hvor x y betegner en -CH=C- eller -CH2~CH-gruppe, R-^betegner et hydrogenatom- eller em methylgruppe, og R betegner en allylgrup-pe, en fenyl-, pyridyl-, eller pyrimidylgruppe- som eventuelt har én eller flere methoxy- r- halogen-, trif luormethy 1- og/eller nijtrosubstitu-enter, en n-propyl- eller n-butyl-gruppe som eventuelt har én eller flere cajrbomethoxy- og/eller nitroguani-dino-substituenter, eller en glycol-tyrosinol-gruppe,karakterisert vedat en aktiv- lysergsyreester av generell formel II: where x y denotes a -CH=C- or -CH2~CH group, R-^ denotes a hydrogen atom or em methyl group, and R denotes an allyl group, a phenyl-, pyridyl-, or pyrimidyl group- which optionally has one or more methoxy-r-halogen, trifluoromethyl 1- and/or nitro-substituents, an n-propyl- or n-butyl group which optionally has one or more cajrbomethoxy- and/or nitroguani- dino-substituents, or a glycol-tyrosinol group, characterized by an activ-lysergic acid ester of general formula II: hvor x~*~^y og JL har de tidligere angitte betydninger, Z betegner halogenatomer og/eller nitrogrupper, og hvor n er en faktor fra 1 - 5, amideres med en forbindelse inneholdende en primær eller sekundær aminogruppe, og om bnskes, at den erholdte forbindelse av generell formel I omdannes til et syreaddisjonssalt ved omsetning med en farmasbytisk akseptabel syre.where x~*~^y and JL have the previously stated meanings, Z denotes halogen atoms and/or nitro groups, and where n is a factor from 1 - 5, is amidated with a compound containing a primary or secondary amino group, and if desired, the obtained compound of general formula I is converted into an acid addition salt by reaction with a pharmaceutically acceptable acid. 2. Fremgangsmåte ifolge krav 1, karakterisert vedat der som aktiv lysergsyreester anvendes den tilsvarende pentaklorfenolester.2. Procedure according to claim 1, characterized in that the corresponding pentachlorophenol ester is used as active lysergic acid ester. 3. Fremgangsmåte ifolge krav 1 eller 2,karakterisert vedat amideringen utfores direkte i reaksjonsblandingen i hvilken den aktive lysergsyreester er dannet, uten isolering av den aktive ester.3. Method according to claim 1 or 2, characterized in that the amidation is carried out directly in the reaction mixture in which the active lysergic acid ester is formed, without isolation of the active ester.
NO430/73A 1972-02-04 1973-02-02 NO133670C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUGO001186 HU164051B (en) 1972-02-04 1972-02-04
HUGO001187 HU163546B (en) 1972-02-04 1972-02-04

Publications (2)

Publication Number Publication Date
NO133670B true NO133670B (en) 1976-03-01
NO133670C NO133670C (en) 1976-06-09

Family

ID=26318474

Family Applications (1)

Application Number Title Priority Date Filing Date
NO430/73A NO133670C (en) 1972-02-04 1973-02-02

Country Status (20)

Country Link
JP (1) JPS5221516B2 (en)
AU (1) AU475943B2 (en)
BE (1) BE794888A (en)
BG (1) BG22832A3 (en)
CA (1) CA994342A (en)
CH (1) CH589079A5 (en)
CS (1) CS191212B2 (en)
DD (1) DD104299A5 (en)
DE (1) DE2305514A1 (en)
DK (1) DK141531B (en)
EG (1) EG10823A (en)
FI (1) FI54118C (en)
FR (1) FR2190440B1 (en)
GB (1) GB1401155A (en)
IL (1) IL41409A (en)
NL (1) NL178256C (en)
NO (1) NO133670C (en)
SE (1) SE421424B (en)
SU (1) SU468419A3 (en)
YU (1) YU36730B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU169073B (en) * 1974-05-28 1976-09-28
HU168914B (en) * 1974-07-30 1976-08-28
HU172649B (en) * 1975-04-24 1978-11-28 Gyogyszerkutato Intezet Process for producing new, biologically active lysergamides
DE2802023A1 (en) * 1977-01-28 1978-08-03 Sandoz Ag NEW ERGOT DERIVATIVES, THEIR PRODUCTION AND USE
JPH0438472U (en) * 1990-07-31 1992-03-31
IT1260156B (en) * 1992-08-03 1996-03-28 Fidia Spa NEURAMINIC ACID DERIVATIVES
MX2013015373A (en) * 2011-06-23 2014-02-11 Map Pharmaceuticals Inc Novel fluoroergoline analogs.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH475252A (en) * 1966-02-08 1969-07-15 Sandoz Ag Process for the production of new lysergic acid derivatives
AT291446B (en) * 1968-11-22 1971-07-12 Richter Gedeon Vegyeszet Process for the preparation of new apovincaminic amides

Also Published As

Publication number Publication date
JPS4886900A (en) 1973-11-15
BE794888A (en) 1973-05-29
NL178256C (en) 1986-02-17
CS191212B2 (en) 1979-06-29
FR2190440A1 (en) 1974-02-01
JPS5221516B2 (en) 1977-06-10
AU475943B2 (en) 1976-09-09
YU26673A (en) 1982-02-25
DD104299A5 (en) 1974-03-05
NO133670C (en) 1976-06-09
GB1401155A (en) 1975-07-16
SU468419A3 (en) 1975-04-25
EG10823A (en) 1976-07-31
FI54118C (en) 1978-10-10
FI54118B (en) 1978-06-30
FR2190440B1 (en) 1976-09-03
NL178256B (en) 1985-09-16
NL7301369A (en) 1973-08-07
CA994342A (en) 1976-08-03
IL41409A (en) 1977-04-29
DE2305514A1 (en) 1973-08-16
AU5163373A (en) 1974-08-01
IL41409A0 (en) 1973-03-30
YU36730B (en) 1984-08-31
DK141531B (en) 1980-04-14
SE421424B (en) 1981-12-21
BG22832A3 (en) 1977-04-20
CH589079A5 (en) 1977-06-30
DK141531C (en) 1980-10-06

Similar Documents

Publication Publication Date Title
DE69713402T2 (en) LIGANDS OF THE NEUROPEPTID Y
KR0142417B1 (en) Tertiary alkyl functionalized piperazine derivatives
JPS6049192B2 (en) New substituted benzamides, their production methods, and psychotropic drugs containing them as active ingredients
IE41838B1 (en) 4-substituted quinazoline cardiac stimulants
JP2008516901A (en) Non-peptide bradykinin antagonist and pharmaceutical composition thereby
KR850000216B1 (en) Process for preparing piperazine derivatives
KR100192833B1 (en) 4-acylaminotyridine derivatives
US5179108A (en) Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application
KR900006742B1 (en) N-(2-oxopyrrolidin-1-yl)-acetyl pipera zine derivatives and drug for senile dementia
NO133670B (en)
IE46802B1 (en) 2-methoxy-5-chloro aniline derivatives
DD143613A5 (en) PROCESS FOR PREPARING 4-AMINO-2-PIPERIDINO-CHINAZOLINE DERIVATIVES
US5519025A (en) 4-indolylpiperazinyl derivatives
US3904633A (en) Lysergic amides
DE2454619A1 (en) PROCESS FOR PRODUCING NEW HETEROCYCLIC COMPOUNDS
NO124430B (en)
KR19990081970A (en) 1-pyrazol-3-yl-ethyl-4-indol-3-yl-piperidine used as a drug acting on the central nervous system
US4329349A (en) 6-C1-4 Alkyl-7-phenyl or substituted phenyl-1,6-naphthyridine-5(6H)-ones
US2970147A (en) 3-hydroxy-nu-(heterocyclic-ethyl)-morphinans
US4576953A (en) Quinoline derivatives
IE63676B1 (en) Process for the preparation of 5-membered nitrogen-containing heteroaromatics
GB2054593A (en) 6-Alkyl-7-phenyl-1,6-naphthyridine- 5(6H)-one derivatives
SU625600A3 (en) Method of producing substituted acetamides or their salts
JPH05255313A (en) N,n&#39;-disubstituted amide derivative
US5272157A (en) Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application